Possibilities for personalised medicine in rheumatoid arthritis: hype or hope.
Judith HeutzPascal Hendrik Pieter de JongPublished in: RMD open (2021)
Knowledge of pathophysiology of rheumatoid arthritis (RA) has improved over the past decades, which resulted in new treatment options and strategies that led to better clinical outcomes. At the same time, we have come to understand that RA is a heterogeneous disease on a clinical as well as a pathophysiological level. Despite this heterogeneity, current management recommendations still adopt a 'one-size-fits-all' treatment approach, where ideally individualised treatment, or personalised medicine, is preferred. The first step towards personalised medicine in RA would be to designate different treatment strategies to distinct clinical or molecular phenotypes of patients. This viewpoint discusses current evidence and elaborates on future possibilities for personalised medicine in RA.
Keyphrases
- rheumatoid arthritis
- disease activity
- ankylosing spondylitis
- interstitial lung disease
- healthcare
- end stage renal disease
- ejection fraction
- newly diagnosed
- systemic lupus erythematosus
- prognostic factors
- peritoneal dialysis
- single cell
- combination therapy
- replacement therapy
- patient reported outcomes
- current status
- patient reported
- light emitting